The Praxis pipeline stems from insights into the genetics of epilepsy and the application of those insights to broader neurological and psychiatric diseases. Current clinical stage programs focus on pediatric epilepsies, mood and anxiety disorders, movement disorders, headache, and pain. Scholars who are selected for this program will engage in all aspects of therapeutics development including translational medicine and biomarker development, toxicology and pharmacovigilance, clinical pharmacology, clinical trial design and execution, and regulatory affairs and will have the opportunity to focus on specific independent projects. This training will prepare candidates for leadership roles in clinical research in academic medicine or industry.

Scholars will be selected by a joint Praxis-Mass General committee. Eligible candidates should have an MD or PhD, with clinical or translational research experience in a therapeutic area related to areas of interest listed above, and should have appointments within the departments of Psychiatry or Neurology at Mass General Brigham. The selected Scholars will divide their time approximately equally over two years between between their academic and clinical committments at Mass General Brigham and their drug development work at Praxis. Scholars will receive salary support and benefits from Praxis in accordance with their percent effort.

Interested applicants should send their CV and a brief (approximately 1 page) cover letter describing their interest in the program to Interviews will be scheduled accordingly, and the entire application process is expected to take approximately 45 days. Applications will be accepted on a rolling basis and up to two positions will be filled.

Questions or requests for additional information may be directed to Program Coordinator Erica Ratti.